|Articles|February 26, 2010

Bomem-Michelson Award

Richard P.Van Duyne,the Charles E.and Emma H. Morrison Professor of Chemistry at Northwestern University,will receive the 2010 Bomem-Michelson Award from the Coblentz Society on Tuesday morning. The award,dedicated to the memory of A.E.Michelson and sponsored by ABB,is presented annually to honor scientists who have advanced the techniques of vibrational,molecular,Raman, or electronic spectroscopy.

Tuesday, March 2, 2010

Room 206A

Richard P.Van Duyne,the Charles E.and Emma H. Morrison Professor of Chemistry at Northwestern University, will receive the 2010 Bomem-Michelson Award from the Coblentz Society on Tuesday morning. The award, dedicated to the memory of A.E. Michelson and sponsored by ABB, is presented annually to honor scientists who have advanced the techniques of vibrational, molecular, Raman, or electronic spectroscopy. Professor Van Duyne is being recognized for the discovery of surface-enhanced Raman spectroscopy (SERS) and his many contributions to the fundamental science and application of SERS.

Van Duyne is widely known for the 1977 discovery of surface-enhanced Raman spectroscopy (SERS). The quest to understand SERS at a fundamental level resulted in Professor Van Duyne’s invention of nanosphere lithography (NSL) to fabricate structurally and optically well-defined SERS-active surfaces. NSL led in turn to the development of ultra sensitive nanosensors based on localized surface plasmon resonance spectroscopy and the field of molecular plasmonics. Most recently, Van Duyne developed the isotopologue proof of single molecule SERS that has put this field on a more sound scientific footing.

Van Duyne received his BS degree from Rensselaer Polytechnic Institute (1967) and a PhD degree in analytical chemistry from the University of North Carolina (1971). He has won numerous awards, including the ACS Award in Analytical Chemistry, the Ellis R. Lippincott Award (2008), the National Science Foundation Creativity Extension Award (2007), L’Oreal Art and Science of Color Prize (2006), ACS Nobel Laureate Signature Award for Graduate Education (2005), the American Physical Society Earle K.Plyler Prize for Molecular Spectroscopy (1996), the Pittsburgh Spectroscopy Award (1991), the Coblentz Society Memorial Prize in Molecular Spectroscopy (1980), and an Alfred P.Sloan Fellowship (1974). He is a member of the American Academy of Arts and Sciences and a fellow of the American Physical Society and the American Association for the Advancement of Science.

Related to this article

Scientist With Portable Spectrometer in Natural Field Setting ©  By Tika -chronicles-stock.adobe.com
The bulky bench-top NIR spectrometer is quietly being dismantled and rebuilt as a wafer-scale photonic chip, a self-calibrating algorithm, and a sensor small enough to ride in a shirt pocket. What once demanded a grating, a moving mirror, and a climate-controlled lab now fits inside a handheld module, a bioreactor probe, or a drone payload, and it increasingly figures out what it is looking at on its own.
Sizing Up the Nanoscale: Measuring Nanocluster Aerosol in Indoor Air
In the first part of a multi-part Q&A, Brandon Boor, the Dr. Margery E. Hoffman Associate Professor in the Lyles School of Civil and Construction Engineering at Purdue University, describes the instrumentation and methodology behind measuring nanoparticle size distributions at the nanocluster scale (1–3 nm) and outlines the technical challenges of acquiring reliable, real-time data at these dimensions.
Human body wireframe on glowing platform undergoing futuristic body scan. © sergray(noAIelemens) -chronicles-stock.adobe.com
Jurgen Popp, Thomas Mayerhofer, and colleagues at Leibniz IPHT and Friedrich Schiller University Jena introduce the Personalized Optical Digital Twin (PODT), a Photonics21 contribution to Europe's Virtual Human Twin ecosystem that connects molecular photonics—Raman blood analysis, coherent Raman tissue imaging, and multimodal endomicroscopy—with longitudinal physiology and clinical data. Drawing on the published multicenter INTELLIGENCE trials, the authors argue that technical feasibility and clinical utility must be evaluated separately as the field moves toward Europe's FP10 research agenda.